One Injection Cuts Bad Cholesterol 62% for Life

Imagine getting one shot that lowers your bad cholesterol by more than half and keeps it down for life. That future just got a lot closer.

Pharmaceutical giant Eli Lilly announced this week that its experimental gene-editing therapy, VERVE-102, reduced LDL cholesterol by up to 62% with a single infusion. Even better, the results lasted at least 18 months in trial participants, with no serious side effects reported.

The treatment works by turning off a gene called PCSK9 that controls how much bad cholesterol your liver removes from your blood. Less PCSK9 means your body naturally clears out more cholesterol on its own.

A small early-stage trial tracked 35 patients who either had heart disease or genetically high cholesterol levels. The highest dose of VERVE-102 cut the PCSK9 protein by up to 88%. The results appeared in the New England Journal of Medicine this week.

"This drug turns off a tiny fraction of DNA, and your LDL cholesterol is lower by 50% for the rest of your life," said Riyaz Patel, an academic cardiologist at University College London. "One and done. This is going to be revolutionary."

Unlike daily statin pills or existing PCSK9 treatments that need regular doses, VERVE-102 appears to create lasting change. Current medications that block PCSK9 only reduce cholesterol between 50% and 60%, and levels can creep back up between doses.

That matters because every moment of high LDL cholesterol exposure increases your lifetime risk of a heart attack, according to healthcare analyst Myles Minter. The treatment could be especially valuable for younger patients with genetic predispositions to high cholesterol.

Heart disease remains the leading cause of death in the United States. High LDL cholesterol contributes to plaque buildup in blood vessels, which can block blood flow to the heart and trigger cardiac events.

Why This Inspires

This isn't just another medication tweaking numbers on a lab report. It represents a fundamental shift in how we might prevent heart disease before it starts.

For decades, managing cholesterol has meant daily pills, lifestyle changes, and watching numbers bounce up and down. VERVE-102 offers something different: a one-time intervention that could protect hearts for a lifetime.

The treatment is still early in development, with a Phase 2 clinical trial expected to begin by the end of this year. Researchers are focusing on patients with premature cardiovascular disease and genetically high cholesterol to determine who benefits most.

Because VERVE-102 permanently alters DNA, scientists are being thoughtful about which patients it suits best. The treatment may not be appropriate for older patients, but could be life-changing for younger people facing decades of elevated cardiac risk.

The implications reach beyond individual patients too. If one treatment can replace years of daily medications, it could reduce healthcare costs and improve quality of life for millions of Americans at risk for heart disease.

A single shot that protects your heart for life once seemed like science fiction, but thanks to gene-editing breakthroughs, it's becoming science fact.